Although there have been numerous attempts to target adaptive immune cells in colon cancer, both with anti-PD-1 and anti-CTLA-4 immunotherapies, this has been unsuccessful in >80% of colorectal cancers. This evidence concerns the gene CTLA4 and colorectal cancer.